WORCESTER, MA –November 19, 2009 (BUSINESS WIRE). Advanced Cell Technology, Inc. (OTCBB: ACTC – News announced today that it filed an Investigational New Drug (IND)…
Worcester, MA, May 19, 2005 – A.C.T. Holdings, Inc. (OTCBB:ACTH.OB) and its wholly-owned subsidiary, Advanced Cell Technology, Inc. (collectively, “ACT”)…
MARLBOROUGH, Mass. — May 16, 2013 – Advanced Cell Technology, Inc.(“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine,…
MARLBOROUGH, MA –November 2, 2010. Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today…
MARLBOROUGH, Mass. — Dec. 19, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field…
Key Patent Covers Fundamental Methods for Producing RPE Cells from Embryonic Stem Cells Including IP Used in Phase I Trial to Treat…
MARLBOROUGH, Mass. — March 1, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative…
Financing Commitment Puts Company on Firmer Financial Footing as it Continues Progress with Three Ongoing Phase I/II Clinical Trials and…
Moorfields Eye Hospital in London Initiates Clinical Trial Using hESC-derived RPE cells MARLBOROUGH, Mass. — Jan. 23, 2012 – Advanced…
Data and Safety Monitoring Board (DSMB) Process Streamlined in the Protocol; Could Accelerate Patient Enrollment and Treatment in European Trial…